Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for CINV Prevention in Gynecologic Cancer
NCT04503668Phase 3Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV), sponsored by University of Michigan Rogel Cancer Center. Started Dec 2020; status: terminated.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04503668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503668.